Krystal sells the first gene therapy for a severe skin-blistering disease.
Krystal Biotech, Inc. (KRYS) is expected to report earnings on Monday, November 2, 2026, before the open. Estimated release time 07:30 ET. Consensus EPS estimate is $1.85.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-03 | Jun 2026 qtr | $1.70 | $1.85 | +8.8% | $119.22M |
| 2026-05-04 | Mar 2026 qtr | $1.45 | $1.91 | — | $116.36M |
| 2026-02-17 | Dec 2025 qtr | $1.62 | $1.77 | +9.3% | $107.11M |
| 2025-11-03 | Sep 2025 qtr | $1.12 | $2.74 | — | $97.80M |
| 2025-08-04 | Jun 2025 qtr | $1.08 | $1.33 | — | $96.04M |
| 2025-05-06 | Mar 2025 qtr | $1.38 | $1.24 | -10.1% | $88.18M |
| 2025-02-19 | Dec 2024 qtr | $1.29 | $1.58 | — | $91.14M |
| 2024-11-04 | Sep 2024 qtr | $0.90 | $0.95 | +5.6% | $83.84M |
KRYS has beaten consensus EPS in 3 of its last 4 scored quarters.
See KRYS on the live calendar →